OptiNose — Investor Presentation (October 2018)
18 slides from OptiNose's investor presentation, Oct 1, 2018
Slide 1: Building a Leading ENT / Allergy Specialty Company
Exhibit 99.1 Building a Leading ENT / Allergy Specialty Company Corporate Presentation O c t o b e r 1 , 2 0 1 8
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Emerging Growth Company with Approved Products
Emerging Growth Company with Approved Products BUILDING A LEADING ENT / ALLERGY SPECIALTY COMPANY XHANCE® presents a significant opportunity in the ENT/Allergy market with the current indication XHANCE offers “pipeline within a product” opportunities Additional business development expected to focus
Slide 4: Optinose EDS Technology is a Platform for Development
Optinose EDS Technology is a Platform for Development Therapy Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Approved XHANCE® (Nasal Polyps) XHANCE® (Chronic Sinusitis) ONZETRA® Xsail® Licensed to Avanir (Migraine) Pharmaceuticals OPN-300 (Autism, Prader- Willi Syndrome) OPN-021 (Narcolepsy, Parkinson’s)
Slide 5: Chronic Rhinosinusitis is an Attractive Market for XHANCE with High Unmet Need
Chronic Rhinosinusitis (CRS) is an Attractive Market for XHANCE…with High Unmet Need 30 Million High Burden US Adults suffer from CRS • Disease persists for many years and up to 10 million of them have nasal • Significant quality of life impact polyps (NP) (comparable to CHF, COPD, Angina) 9.75 Mill
Slide 6: XHANCE: Chronic Sinusitis Follow-on Indication (sNDA)
XHANCE: “Chronic Sinusitis” Follow-on Indication (sNDA) Met with FDA Selection of CRO First patients regarding CS and study expected to study design locations enroll in 4Q 2018 Chronic Sinusitis trial design expected to include co-primary endpoints: both an objective measure of inflammation and a su
Slide 7: XHANCE Launch Update
XHANCE Launch Update
Slide 8: Early Launch Observations
Early Launch Observations Critical Insights and Takeaways ▪ XHANCE is fulfilling its clinical promise (patient) ▪ Perception of differentiation on device and deposition has been established – can now shift communication emphasis to efficacy (physician) ▪ Payor coverage is as-expected and continues t
Slide 9: Encouraging Feedback From Xperience Patient Survey
Encouraging Feedback From Xperience Patient Survey Patient Responses Prior to Month 2 Refill Total Prior User of Prior User of Respondents Flonase / Nasonex Budesonide Rinse (N=2,733) (n=820) (N=175) Patient Satisfaction 89% 90% 90% Experience Symptom Improvement 80% 79% 68% Prefer XHANCE 77% 82% 83
Slide 10: Success in Achieving Strong Perceived Differentiation on Device and Deposition
Success in Achieving Strong Perceived Differentiation on Device and Deposition* Device Deposition Data Optinose EDS w/Exhalation Specialty-specific detail aids Nasal Spray w/o Exhalation Phase 3 publication dissemination Communication emphasis now shifting to driving efficacy perceptions of XHANCE *
Slide 11: Examples of Positive XHANCE Physician Feedback
Examples of Positive XHANCE Physician Feedback * “I had a patient who had been on everything and was begging for surgery. I said let’s just try XHANCE for a month. We scheduled surgery but the patient came back very happy and we cancelled the surgery.” - ENT “I had a severe patient and my goal was f
Slide 12: XHANCE Commercial Market Access
XHANCE Commercial Market Access XHANCE Overall Access: September 2018 • Nationally, we believe 78% of commercial lives are currently in a plan where XHANCE is covered. 22% • We continue to focus on access with minimized hassle for 78% prescribers and patients. • We are working towards achieving “lim
Slide 13: Key Focus Areas Addressed in Late August to Accelerate XHANCE Performance
Key Focus Areas Addressed in Late August to Accelerate XHANCE Performance 1 • Taking advantage of early in-market experience with XHANCE, an updated and Prioritized Patient Type rigorous market analysis and segmentation was performed to define specific, within ENT / Allergy readily-identifiable, pat
Slide 14: Patient Support Programs are Essential to Address Affordability and Access
Patient Support Programs are Essential to Address Physician Perceptions Regarding Affordability and Access for XHANCE March through June July through mid-August Mid-August forward XPERIENCE XTENDED Patient Support ▪ $0 co-pay for initial Rx (in ▪ $0 for the first two lieu of samples) for all prescri
Slide 15: Strong Initial Breadth of XHANCE New Prescribers
Strong Initial Breadth of XHANCE New Prescribers Cumulative Physician Trialists August Weekly New Prescribers (Through the Week Ended August 31, 2018) (Through the Week Ended August 31, 2018) 3,500 100 As of August 31, ~42% of Week out of field for 91 called physicians have 3,069 Sales Meetings to r
Slide 16: Impact of Seasonality, Sampling and Xperience Sunset Absorbed in July
Impact of market seasonality, heavy sampling, and sunsetting of XPERIENCE program was absorbed in July: encouraging early signals of growth following late-August implementation of acceleration plan XHANCE Monthly TRx Volume August Weekly TRx Volume (Through August 2018) (Through August 31, 2018) +12
Slide 17: Investor Relations
Investor Relations – NASDAQ: OPTN At 30 June 2018: Analyst Coverage1 – $245 million in cash – Long-term debt: $75 million BMO: Gary Nachman – 41.1 million common shares o/s Jefferies: David Steinberg – 8.0 million options & warrants o/s Cantor Fitzgerald: William Tanner Optinose Investor Contact Jon
Slide 18: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Corporate Presentation O c t o b e r 1 , 2 0 1 8